The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...

Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Rosen Law Firm PAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...